Literature DB >> 29788168

Nivolumab combined with ruxolitinib: antagonism or synergy?

P E Debureaux1, J Arrondeau2, D Bouscary3, F Goldwasser1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29788168     DOI: 10.1093/annonc/mdy077

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.

Authors:  Eleni Panagioti; Cheyne Kurokawa; Kimberly Viker; Arun Ammayappan; S Keith Anderson; Sotiris Sotiriou; Kyriakos Chatzopoulos; Katayoun Ayasoufi; Aaron J Johnson; Ianko D Iankov; Evanthia Galanis
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

2.  Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma.

Authors:  Luciana Buonerba; Rossella Di Trolio; Antonio Grimaldi; Aniello Tucci; Emilio Leo; Concetta Ingenito; Ferdinando Costabile; Gianluca Ragone; Beatrice Savastano; Maria Teresa Uzzauto; Valeria Belsito Petrizzi; Giuseppe Di Lorenzo
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.